November 26, 2024 – Abbott broadcasts the primary affected person procedures with its experimental transcatheter aortic valve implantation (TAVI) balloon expandable system for the therapy of symptomatic extreme aortic stenosis. This experimental Abbott TAVI system is step one towards Abbott's software-driven, balloon-expandable TAVI system and is designed to offer a basis for synthetic intelligence (AI)-guided procedures. As soon as the experimental balloon expandable system completes scientific growth and receives regulatory approval, Abbott's structural coronary heart portfolio will present physicians with one other TAVI administration choice to fulfill affected person wants, together with the corporate's Navitor™ TAVI system the corporate, which is already commercially out there.

Proceed studying